Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Rituximab

Aliases
ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10 (43 other aliases)
Name
rituximab
Target
CD20
FDA Approved
Yes
Ema approved
Status
0

147 clinical trials

4 organizations

2 drugs

2 abstracts

100 indications

4 documents

Indication
Chronic Lymphocytic Leukemia
Indication
Waldenstrom Macroglobulinemia
Indication
mantle cell lymphoma
Indication
Marginal Zone Lymphoma
Indication
B-cell Lymphoma
Indication
Small Lymphocytic Lymphoma
Indication
Refractory aggressive B-cell lymphoma
Indication
Diffuse Large B-Cell Lymphoma
Indication
Follicular Lymphoma
Indication
Non-Hodgkin Lymphoma
Indication
Diffuse Large B-cell Lymphoma
Indication
lymphoma
Indication
Mantle Cell
Indication
Relapsed/Refractory B-Cell Lymphoma
Indication
Mantle Cell Lymphoma
Indication
Lupus Nephritis
Indication
B-cell Non-Hodgkin Lymphoma
Indication
Transplant Rejection
Indication
Large B-Cell
Indication
Diffuse
Indication
Non Hodgkin's Lymphoma
Indication
DLBCL
Indication
Rapidly Progressive Glomerulonephritis
Indication
Diffuse large B-cell lymphoma (DLBCL)
Indication
B-cell
Indication
Non-Hodgkin lymphoma
Indication
Indolent Non-Hodgkin Lymphoma
Indication
B-Cell Non-Hodgkin Lymphoma
Indication
Metastatic Cancer
Indication
Solid Tumor
Indication
Advanced Cancer
Indication
non-Hodgkin lymphoma
Indication
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Indication
B-cell lymphoma
Indication
Mature B-Cell Non-Hodgkin Lymphoma
Indication
ANCA Associated Vasculitis
Indication
Rheumatoid Arthritis
Indication
Glomerulonephritis
Indication
Membranous nephropathy
Indication
Non-Hodgkin
Indication
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Indication
Mucopolysaccharidosis
Indication
Mucopolysaccharidosis II (MPS II)
Indication
small lymphocytic lymphoma
Indication
Marginal Zone B Cell Lymphoma
Indication
High Grade Non-Hodgkin's Lymphoma
Indication
Multiple Myeloma
Indication
Thrombotic Thrombocytopenic Purpura
Indication
Aggressive Lymphoma
Indication
Cancer
Indication
Indolent Non-Hodgkin's Lymphoma
Indication
Acute Myeloid Leukemia
Indication
Malignant Tumors
Indication
B-Cell Malignancies
Indication
Chronic Lymphocytic
Indication
Leukemia
Indication
Lymphocytic
Indication
Chronic
Indication
Kidney Failure
Indication
Burkitt lymphoma
Indication
Multicentric Castleman Disease
Indication
Rheumatic Heart Disease in Children
Indication
Primary Mediastinal Large B-Cell Lymphoma
Indication
Recurrent Transformed Chronic Lymphocytic Leukemia
Indication
Refractory Transformed Chronic Lymphocytic Leukemia
Indication
Richter syndrome
Indication
CCND1
Indication
CCND2
Indication
CCND3
Indication
CD20-positive
Indication
Steroid-Dependent Nephrotic Syndrome
Indication
Nephrotic Syndrome
Indication
Primary Immune Thrombocytopenia
Indication
Myasthenia Gravis
Indication
Membranous Nephropathy
Indication
Multiple Sclerosis
Indication
Relapsing-remitting multiple sclerosis
Indication
Hepatocellular Carcinoma
Indication
Nephrotic Syndrome, Idiopathic
Indication
Anti-MAG Neuropathy
Indication
Mature B-cell Non-Hodgkin Lymphoma
Indication
Immunocytoma
Indication
Lymphoma
Indication
Anaemia
Indication
Sickle Cell
Indication
Aggressive B-Cell Lymphoma
Indication
Recurrent B-Cell Non-Hodgkin Lymphoma
Indication
Grade 2 Follicular Lymphoma
Indication
Mental Illness
Indication
MALT lymphoma
Indication
Acute Lymphoblastic Leukemia
Indication
Relapse
Indication
High-Grade B-Cell Lymphoma
Indication
IgA Nephropathy
Indication
Double Express Diffuse Large B-cell Lymphoma
Indication
nephrotic syndrome
Indication
Proteinuria
Indication
autoimmune disease
Indication
Glomerular Disease
Indication
Primary CNS Lymphoma
Drug
rituximab
Drug
Ruxience
Clinical trial
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2027-09-01
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation
Status: Active (not recruiting), Estimated PCD: 2024-03-19
Clinical trial
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Status: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Phase III, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of SIBP-02 (Rituximab Biosimilar) and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Status: Terminated, Estimated PCD: 2022-03-22
Clinical trial
A Randomized, Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma
Status: Recruiting, Estimated PCD: 2027-08-25
Clinical trial
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)
Status: Completed, Estimated PCD: 2021-08-24
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Status: Recruiting, Estimated PCD: 2028-10-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-10-28
Clinical trial
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Status: Recruiting, Estimated PCD: 2029-01-17
Clinical trial
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Status: Terminated, Estimated PCD: 2023-03-20
Clinical trial
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination With Rituximab and Bendamustine (BR) vs. BR in Subjects With Treatment-Naїve Mantle Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2034-12-25
Clinical trial
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-01-30
Clinical trial
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
Status: Recruiting, Estimated PCD: 2024-11-14
Clinical trial
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Terminated, Estimated PCD: 2023-12-12
Clinical trial
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
Status: Not yet recruiting, Estimated PCD: 2026-03-15
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)
Status: Not yet recruiting, Estimated PCD: 2031-10-16
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis
Status: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)
Status: Recruiting, Estimated PCD: 2026-01-26
Clinical trial
A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Status: Not yet recruiting, Estimated PCD: 2028-08-14
Clinical trial
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-10
Clinical trial
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Status: Recruiting, Estimated PCD: 2029-10-04
Clinical trial
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)
Status: Recruiting, Estimated PCD: 2027-07-06
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3
Status: Active (not recruiting), Estimated PCD: 2020-08-31
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adult Patients With Relapsed/Refractory DLBCL and iNHL Who Are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT)
Status: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Status: Recruiting, Estimated PCD: 2028-09-18
Clinical trial
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Status: Completed, Estimated PCD: 2024-01-22
Clinical trial
A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
Status: Active (not recruiting), Estimated PCD: 2027-02-05
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Clinical trial
A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib Versus Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2).
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Status: Active (not recruiting), Estimated PCD: 2022-02-01
Clinical trial
A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin (POLA) Plus Rituximab (R), Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-08-25
Clinical trial
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2027-10-15
Clinical trial
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
Status: Recruiting, Estimated PCD: 2027-06-21
Clinical trial
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis
Status: Not yet recruiting, Estimated PCD: 2027-08-27
Clinical trial
A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-19
Clinical trial
Randomized Double Blind Phase I Trial Comparing Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Rituximab (Mabscale LLC, Russia)+ Methotrexate+ Folic Acid and MabThera® Methotrexate+ Folic Acid in Adult Patients With Moderate or Severe Rheumatoid Arthritis With Insufficient Response to Treatment Tumor Necrosis Factor (TNF-α)
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)
Status: Recruiting, Estimated PCD: 2030-01-24
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-27
Clinical trial
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Terminated, Estimated PCD: 2023-09-01
Clinical trial
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Status: Recruiting, Estimated PCD: 2029-09-30
Clinical trial
A Randomized, Controlled, Open, Multicenter Phase 3 Study to Evaluate ICP-022 Versus Chlorambucil Combined With Rituximab for Primary Treatment of Chronic Lymphocytic Leukemia(CLL)/ Small Lymphocytic Lymphoma(SLL)
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Status: Recruiting, Estimated PCD: 2026-04-17
Clinical trial
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Status: Recruiting, Estimated PCD: 2029-11-15
Clinical trial
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-12-13
Clinical trial
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2032-11-26
Clinical trial
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
Status: Recruiting, Estimated PCD: 2027-05-19
Clinical trial
An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing Persistent Neutralizing Antibodies
Status: Recruiting, Estimated PCD: 2027-06-15
Clinical trial
A Multicenter, Open Phase Ib Study of the Safety and Efficacy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study
Status: Withdrawn, Estimated PCD: 2023-03-15
Clinical trial
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy
Status: Terminated, Estimated PCD: 2023-01-20
Clinical trial
A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL
Status: Terminated, Estimated PCD: 2023-03-29
Clinical trial
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2021-06-11
Clinical trial
A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2018-12-19
Clinical trial
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma
Status: Completed, Estimated PCD: 2018-06-22
Clinical trial
A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2019-12-31
Clinical trial
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
Status: Active (not recruiting), Estimated PCD: 2023-03-28
Clinical trial
A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-03-28
Clinical trial
An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status: Completed, Estimated PCD: 2021-05-19
Clinical trial
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2023-04-26
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Status: Terminated, Estimated PCD: 2021-07-12
Clinical trial
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
Status: Terminated, Estimated PCD: 2023-10-23
Clinical trial
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2021-10-21
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Terminated, Estimated PCD: 2023-09-27
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers
Status: Active (not recruiting), Estimated PCD: 2024-06-20
Clinical trial
Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
RIM - Rituximab in Maintenance
Status: Completed, Estimated PCD: 2014-06-01
Clinical trial
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: , Estimated PCD: 2025-12-01
Clinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2019-03-15
Clinical trial
A Phase 1 Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Terminated, Estimated PCD: 2022-03-31
Clinical trial
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Terminated, Estimated PCD: 2023-09-15
Clinical trial
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Completed, Estimated PCD: 2022-06-23
Clinical trial
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Status: Withdrawn, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Status: Completed, Estimated PCD: 2021-04-12
Clinical trial
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-04-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
Status: Not yet recruiting, Estimated PCD: 2027-09-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status: Terminated, Estimated PCD: 2016-12-01
Clinical trial
A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors
Status: , Estimated PCD: 2024-12-01
Clinical trial
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Status: Active (not recruiting), Estimated PCD: 2021-05-07
Clinical trial
A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Status: Terminated, Estimated PCD: 2017-01-17
Clinical trial
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-08-04
Clinical trial
A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab
Status: Completed, Estimated PCD: 2017-05-08
Clinical trial
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2020-03-09
Clinical trial
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Status: Completed, Estimated PCD: 2019-03-06
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Clinical trial
A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda
Status: Terminated, Estimated PCD: 2023-07-26
Clinical trial
Open-label, Randomized Controlled Trial to Assess Efficacy and Safety of Rituximab in Patients With Acute Rheumatic Fever in Africa
Status: , Estimated PCD: 2024-09-30
Clinical trial
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In
Status: Withdrawn, Estimated PCD: 2029-12-29
Clinical trial
Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : a Double-blind Multicenter Randomized Controlled Study
Status: Recruiting, Estimated PCD: 2027-10-18
Clinical trial
A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition to Rituximab in Adult Patients With Persistent or Chronic Immune Thrombocytopenia (ITP)
Status: Recruiting, Estimated PCD: 2026-11-14
Clinical trial
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Prospective, Randomized, Multicenter Clinical Trial Comparing the Efficacy and Safety of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in Primary Membranous Nephropathy
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
Prospective, Single-arm, Phase II Clinical Study of Rituximab, Lenalidomide, and Zanubrutinib Combination Regimen Followed by Immunochemotherapy in the Treatment of Elderly Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Status: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
A Study on the Efficacy and Safety of Rituximab When Combined With Prior Targeted Therapy and Checkpoint Immunotherapy as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome （PRIME Study）
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas
Status: Active (not recruiting), Estimated PCD: 2030-04-01
Clinical trial
Siplizumab-based Conditioning for Hematopoietic Stem Cell Transplantation in Patients With Advanced Sickle Cell Disease (CD2 SCD)
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution
Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2027-04-04
Clinical trial
Phase III Randomized, Multicenter Open Label Study to Evaluate the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.
Status: Not yet recruiting, Estimated PCD: 2026-01-15
Clinical trial
Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)
Status: Active (not recruiting), Estimated PCD: 2016-03-01
Clinical trial
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-01-05
Clinical trial
A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Single-arm、Multicenter、Open-label、Phase II Clinical Study of the Combination of Rituximab、Chidamide、Zanubrutinib-induced and CHOP Therapy for Untreated Dual-expressing Diffuse Large B Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With Primary CNS Diffuse Large B-cell Lymphoma (Nickname: Lemon-C Study)
Status: Recruiting, Estimated PCD: 2024-11-02
Clinical trial
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20182
Clinical trial
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis. Two-stage Interventional, Prospective, Randomized, Controlled, Open Label, Parallel-group Phase I/II Trial in Patients With Active, ACPA-positive and Treatment Refractory Rheumatoid Arthritis
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Document
DailyMed Label: Ruxience
Organization
Pfizer Laboratories Div Pfizer Inc
Document
DailyMed Label: Riabni
Organization
Amgen Inc
Document
DailyMed Label: Rituxan Hycela
Organization
Genentech, Inc.
Document
DailyMed Label: Truxima
Organization
Cephalon, Inc.